Lisdexamfetamine (Elvanse) Explained: How It Differs From Methylphenidate

Lisdexamfetamine is the long-acting amphetamine-class stimulant licensed for ADHD in the UK. It is sold as Elvanse, a single brand licensed from age 6 across children, adolescents and adults since the separate Elvanse Adult presentation was consolidated into it in late 2025 ^[2]. This article explains how the prodrug mechanism works, how it differs pharmacologically from methylphenidate, what a trial usually feels like, and where lisdexamfetamine fits in the NICE NG87 pathway.

What lisdexamfetamine is

Lisdexamfetamine is a prodrug, which means the active substance is inactive in the form that is swallowed. After absorption, lisdexamfetamine is metabolised in the body (mainly by red blood cells) to release dexamfetamine, the active drug ^[2]. This conversion happens gradually, which is why lisdexamfetamine produces a smoother and longer-acting effect than immediate-release dexamfetamine, despite the active molecule being the same.

The prodrug design has two practical implications. First, the onset is slower and the peak is gentler than with immediate-release stimulants. Second, the route of administration is locked to oral dosing; lisdexamfetamine cannot be made to act faster or differently by alternative routes, which is part of why it carries a slightly lower abuse-potential profile than direct amphetamines ^[2]. It remains a Schedule 2 controlled drug.

How it differs from methylphenidate

Both methylphenidate and lisdexamfetamine increase dopamine and noradrenaline activity in the brain, but they do so through different mechanisms ^[5]:

• Methylphenidate works mainly by blocking the dopamine transporter and the noradrenaline transporter, so the chemicals already released stay in the synapse for longer.
• Lisdexamfetamine, once converted to dexamfetamine, also blocks reuptake and additionally causes the presynaptic neuron to release more dopamine and noradrenaline.

The clinical effect is broadly similar: improvements in attention, working memory, task initiation and emotional regulation. The differences in mechanism are why a patient can respond well to one and not the other, and why a switch between the two families is the usual second step where the first stimulant has not worked ^[4].

The Cortese 2018 network meta-analysis found that amphetamines, including lisdexamfetamine, ranked highest on efficacy in the adult ADHD trials it included, while methylphenidate was the best-tolerated option in children and adolescents ^[4]. NICE NG87 reflects this: methylphenidate is the usual first-line stimulant in children and adolescents, while either methylphenidate or lisdexamfetamine can be chosen as first-line in adults ^[1].

The UK formulations

Lisdexamfetamine comes as a single modified-release capsule taken once in the morning. The UK brand is Elvanse, licensed from age 6 for children, adolescents and adults ^[2]. Until late 2025 the adult presentation was sold separately as Elvanse Adult; the manufacturer has since consolidated the range into the single Elvanse brand, so adults are now prescribed Elvanse.

Prescribing practice in adults still often looks for a documented methylphenidate trial before lisdexamfetamine is considered, reflecting the previous adult licence wording and the NICE NG87 pathway, although clinical judgement on grounds of suitability can override this where appropriate.

The active duration is typically ten to thirteen hours from a single morning dose. The morning timing is important because lisdexamfetamine taken later in the day reliably disrupts sleep.

Vyvanse is the US brand for the same molecule. Vyvanse is not licensed in the UK; UK patients are prescribed Elvanse. Tyvense is the Irish brand and is also not the UK option.

What to expect from a trial

Specific doses are a prescribing decision and depend on age, weight and clinical picture. The shape of ADHD medication and titration with NeuroFX with lisdexamfetamine usually looks like:

• A low starting dose taken once in the morning, ideally with breakfast or shortly after
• A short period (often a week or two) to let initial effects settle
• Planned dose increases at intervals where benefit is incomplete and tolerability is good
• A formal review at around six weeks once a steady working dose is reached ^[1]
• Subsequent review at three months and then at agreed intervals

The first dose often produces a noticeable effect within the first morning, which is sometimes described as feeling clearer-headed and more able to start a task. This first-day effect can mislead patients into expecting the full benefit immediately; full clinical benefit usually emerges across several weeks of structured titration ^[4].

A calm guide to your first six months on stimulants covers the practical detail of what the first stretch looks like.

Common effects to expect

The BNF lists the common adverse effects of lisdexamfetamine ^[2]. The pattern is broadly similar to methylphenidate, with some characteristic differences:

• Reduced appetite, often more pronounced than with methylphenidate, particularly through lunch
• Difficulty getting to sleep, particularly where the dose is taken after early morning
• Dry mouth
• A small rise in resting heart rate and blood pressure
• Headache, usually transient
• Occasional irritability or low mood as the dose wears off in late afternoon
• In children, slowed growth in weight; sometimes in height; usually returns to expected trajectory after stopping ^[2]

The longer duration of action means that the trade-off versus methylphenidate is often: smoother coverage across the day, but a longer tail of side effects (notably appetite suppression and sleep disturbance). For some patients this is the right balance; for others, methylphenidate suits better.

Where lisdexamfetamine fits in the NICE pathway

NICE NG87 recommends a structured medication pathway for ADHD ^[1]. For children and adolescents, methylphenidate is usually first-line; lisdexamfetamine is the usual second-line stimulant where methylphenidate has not worked or has not been tolerated. For adults, the order between methylphenidate and lisdexamfetamine is more flexible and clinical judgement plays a larger role.

Switching from methylphenidate to lisdexamfetamine is the most common medication change in ADHD. Switching the other way is also done. Specialist input shapes the order and the timing of switches.

Practical notes

• Lisdexamfetamine is a Schedule 2 controlled drug; the prescribing and dispensing rules are the same as for methylphenidate and dexamfetamine.
• The capsule contents can be dissolved in water or soft food where swallowing is a problem; the BNF and the patient information leaflet have specific guidance ^[2].
• Late dosing is the most common cause of new-onset insomnia in patients on lisdexamfetamine. Take it as early in the morning as practical.
• Eating a sufficient breakfast before the medication takes effect helps offset the lunchtime appetite suppression that follows.

What this means in practice

• Lisdexamfetamine is the long-acting amphetamine-class stimulant in the UK and the usual second-line option after methylphenidate in children and adolescents.
• The prodrug mechanism produces a smooth, single morning dose covering most of the day.
• A switch from methylphenidate to lisdexamfetamine is the usual second step where the first stimulant has not worked.
• Most common side effects settle within the first two weeks; the longer duration of action means side effects also last longer.
• Late dosing is the most common cause of insomnia on lisdexamfetamine. Take it early.

When to speak to a professional

Speak to your GP, your prescriber or NHS 111 if a new symptom appears that worries you, if your blood pressure or heart rate feels noticeably different, or if changes to mood, sleep or appetite are not settling. Seek urgent help via 999 or A&E for chest pain, shortness of breath, fainting or any acute mental health crisis. For private ADHD assessment for adults and children aged 6 and upwards NeuroFX provides private adult ADHD assessment and specialist initiation of lisdexamfetamine where appropriate.

Sources

1. NICE. Attention deficit hyperactivity disorder: diagnosis and management. NG87. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng87
2. British National Formulary. Lisdexamfetamine mesilate. https://bnf.nice.org.uk/drugs/lisdexamfetamine-mesilate/
3. British National Formulary. Dexamfetamine sulfate. https://bnf.nice.org.uk/drugs/dexamfetamine-sulfate/
4. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit/hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738.
5. Faraone SV, Banaschewski T, Coghill D, et al. The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neuroscience and Biobehavioral Reviews. 2021;128:789-818.